Category Archives: ARV-based Intervention

Unprepared, unwilling and unethical

How a lack of leadership in HIV prevention is failing those at risk of infection in the UK (and beyond) In July 2012, the US Food and Drug Administration took a landmark decision when it approved the use of the antiviral Truvada for the prevention

MSMGF: Good Gays get a Blue Ribbon, Bad Gays Bear their Cross

There are posts more difficult than other to write, not so much because of their subject, but because they are critical of HIV prevention interventions devised by fellow prevention activists. This will be another one of those difficult posts. However, on World AIDS Day, as

France Leads the Way with PrEP Approval 5 years after iPrEX

PrEP has arrived… in France! Marisol Touraine, the French Health Minister announced today that the drug Truvada (manufactured by Gilead) is soon to be approved for the prevention of HIV infection (Pre-Exposure Prophylaxis) . “I welcome the publication a temporary recommendation of use of Truvada, a

“On PrEP”

It has now been 6 months since the PROUD and IPERGAY clinical studies investigating Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection had to change course due to the success of the antiretrovirals (ARV) used in these trials to prevent HIV acquisition in HIV

Switch to our mobile site